164 related articles for article (PubMed ID: 19393833)
21. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.
Armstrong F; Duplantier MM; Trempat P; Hieblot C; Lamant L; Espinos E; Racaud-Sultan C; Allouche M; Campo E; Delsol G; Touriol C
Oncogene; 2004 Aug; 23(36):6071-82. PubMed ID: 15208656
[TBL] [Abstract][Full Text] [Related]
24. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
25. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
[TBL] [Abstract][Full Text] [Related]
26. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
[TBL] [Abstract][Full Text] [Related]
27. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
28. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
29. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
30. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
[TBL] [Abstract][Full Text] [Related]
31. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
32. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
34. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ALK signaling for cancer therapy.
Mossé YP; Wood A; Maris JM
Clin Cancer Res; 2009 Sep; 15(18):5609-14. PubMed ID: 19737948
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
[TBL] [Abstract][Full Text] [Related]
37. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
38. Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells.
Gouzi JY; Moog-Lutz C; Vigny M; Brunet-de Carvalho N
J Cell Sci; 2005 Dec; 118(Pt 24):5811-23. PubMed ID: 16317043
[TBL] [Abstract][Full Text] [Related]
39. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
40. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]